AC
FATE icon

Amia Capital’s Fate Therapeutics FATE Stock Holding History

Amia Capital’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-10,209
Closed -$408K – 15
2020
Q3 		$408K Buy
10,209
+3,371
+49% +$118K 0.47% 23
2020
Q2 		$235K Buy
+6,838
New +$204K 0.19% 30

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Amia Capital's FATE Position: Q4 2020 in Review

Amia Capital sold out of Fate Therapeutics (FATE) in Q4 2020, closing a stake of 10,209 shares — an estimated $408K sold.

Amia Capital first reported a position in FATE in Q2 2020 and held it in 2 quarters. The position peaked at $408K in Q3 2020. 248 funds tracked by Wall St. Rank hold FATE as of Q4 2020.

  • Amia Capital reported no remaining Fate Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Amia Capital sold 10,209 Fate Therapeutics shares in Q4 2020, an estimated $408K.
  • Amia Capital first reported a position in Fate Therapeutics in Q2 2020 and held it in 2 quarters.
  • Amia Capital's Fate Therapeutics position peaked at $408K in Q3 2020.
  • 248 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2020.

Based on Amia Capital's 13F filing for Q4 2020, filed 11 Feb 2021.